Prostaglandin D2 induces apoptosis of human osteoclasts through ERK1/2 and Akt signaling pathways

Bone

Volumn 60, Issue , 2014, Pages 112-121

  Yue, Li ^a   Haroun, Sonia ^a   Parent, Jean Luc ^a   De Brum Fernandes, Artur J ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

Arrestin; Akt; Apoptosis; ERK1 2; Osteoclasts; Prostaglandin D2

Indexed keywords

BETA ARRESTIN 1; CASPASE 3; DP RECEPTOR; I KAPPA B KINASE; I KAPPA B KINASE 2; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NAPROXEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROSTAGLANDIN D2; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; PROSTANOID RECEPTOR; PROTEIN KINASE B; RECEPTOR BLOCKING AGENT; SERINE; T LYMPHOCYTE RECEPTOR; THREONINE; THYROXINE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOCLAST; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTAGLANDIN SYNTHESIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AKT; APOPTOSIS; ERK1/2; OSTEOCLASTS; PROSTAGLANDIN D(2); Β-ARRESTIN;

ANIMALS; APOPTOSIS; ARRESTINS; CATTLE; CELL DIFFERENTIATION; HUMANS; I-KAPPA B KINASE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NF-KAPPA B; OSTEOCLASTS; PHOSPHORYLATION; PHOSPHOSERINE; PROSTAGLANDIN D2; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; SIGNAL TRANSDUCTION;

EID: 84891137437     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.12.011     Document Type: Article

References (66)

1. Singh A., Mehdi A.A., Srivastava R.N., Verma N.S. Immunoregulation of bone remodelling. Int J Crit Illn Inj Sci 2012, 2:75-81.
2. Nakanishi A., Hie M., Iitsuka N., Tsukamoto I. A crucial role for reactive oxygen species in macrophage colony-stimulating factor-induced RANK expression in osteoclastic differentiation. Int J Mol Med 2013, 31:874-880.
3. Ikeda F., Matsubara T., Tsurukai T., Hata K., Nishimura R., Yoneda T. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts. J Bone Miner Res 2008, 23:907-914.
4. Kudo O., Fujikawa Y., Itonaga I., Sabokbar A., Torisu T., Athanasou N.A. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. J Pathol 2002, 198:220-227.
5. Kudo O., Sabokbar A., Pocock A., Itonaga I., Fujikawa Y., Athanasou N.A. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003, 32:1-7.
6. Krum S.A., Miranda-Carboni G.A., Hauschka P.V., Carroll J.S., Lane T.F., Freedman L.P., et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008, 27:535-545.
7. Houde N., Chamoux E., Bisson M., Roux S. Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim. J Biol Chem 2009, 284:23397-23404.
8. Huang W., O'Keefe R.J., Schwarz E.M. Exposure to receptor-activator of NFkappaB ligand renders pre-osteoclasts resistant to IFN-gamma by inducing terminal differentiation. Arthritis Res Ther 2003, 5:R49-R59.
9. Bendixen A.C., Shevde N.K., Dienger K.M., Willson T.M., Funk C.D., Pike J.W. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci U S A 2001, 98:2443-2448.
10. Horwood N.J., Elliott J., Martin T.J., Gillespie M.T. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol 2001, 166:4915-4921.
11. Lee S.E., Chung W.J., Kwak H.B., Chung C.H., Kwack K.B., Lee Z.H., et al. Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 2001, 276:49343-49349.
12. Abbas S., Abu-Amer Y. Dominant-negative IkappaB facilitates apoptosis of osteoclasts by tumor necrosis factor-alpha. J Biol Chem 2003, 278:20077-20082.
13. Penolazzi L., Lambertini E., Borgatti M., Piva R., Cozzani M., Giovannini I., et al. Decoy oligodeoxynucleotides targeting NF-kappaB transcription factors: induction of apoptosis in human primary osteoclasts. Biochem Pharmacol 2003, 66:1189-1198.
14. Xing L., Venegas A.M., Chen A., Garrett-Beal L., Boyce B.F., Varmus H.E., et al. Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev 2001, 15:241-253.
15. Recchia I., Rucci N., Funari A., Migliaccio S., Taranta A., Longo M., et al. Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. Bone 2004, 34:65-79.
16. Gingery A., Bradley E., Shaw A., Oursler M.J. Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem 2003, 89:165-179.
17. Gingery A., Bradley E.W., Pederson L., Ruan M., Horwood N.J., Oursler M.J. TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp Cell Res 2008, 314:2725-2738.
18. Fukuda A., Hikita A., Wakeyama H., Akiyama T., Oda H., Nakamura K., et al. Regulation of osteoclast apoptosis and motility by small GTPase binding protein Rac1. J Bone Miner Res 2005, 20:2245-2253.
19. Nakamura H., Hirata A., Tsuji T., Yamamoto T. Role of osteoclast extracellular signal-regulated kinase (ERK) in cell survival and maintenance of cell polarity. J Bone Miner Res 2003, 18:1198-1205.
20. Miyazaki T., Katagiri H., Kanegae Y., Takayanagi H., Sawada Y., Yamamoto A., et al. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 2000, 148:333-342.
21. Erl W., Weber C., Zernecke A., Neuzil J., Vosseler C.A., Kim H.J., et al. Cyclopentenone prostaglandins induce endothelial cell apoptosis independent of the peroxisome proliferator-activated receptor-gamma. Eur J Immunol 2004, 34:241-250.
22. Papadimitriou A., King A.J., Jones P.M., Persaud S.J. Anti-apoptotic effects of arachidonic acid and prostaglandin E2 in pancreatic beta-cells. Cell Physiol Biochem 2007, 20:607-616.
23. 2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gamma-independent mechanism. J Immunol 2002, 168:6232-6243.
24. Xue L., Barrow A., Pettipher R. Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway. J Immunol 2009, 182:7580-7586.
25. 2 receptors, DP and CRTH2, in human eosinophil migration. Ann Allergy Asthma Immunol 2011, 106:511-517.
26. 2 receptors DP and CRTH2 in the pathogenesis of asthma. Curr Mol Med 2008, 8:365-375.
27. 2 synthase induces apoptosis in PC12 neuronal cells. Neuroreport 2001, 12:2623-2628.
28. Wang J.J., Mak O.T. Induction of apoptosis in non-small cell lung carcinoma A549 cells by PGD(2) metabolite, 15d-PGJ(2). Cell Biol Int 2011, 35:1089-1096.
29. Chen Y.C., Shen S.C., Tsai S.H. Prostaglandin D(2) and J(2) induce apoptosis in human leukemia cells via activation of the caspase 3 cascade and production of reactive oxygen species. Biochim Biophys Acta 2005, 1743:291-304.
30. 2 receptors CRTH2 and DP. J Allergy Clin Immunol 2001, 108:982-988.
31. 2 induces apoptosis of human osteoclasts by activating the CRTH2 receptor and the intrinsic apoptosis pathway. Bone 2012, 51:338-346.
32. 2 receptors control osteoclastogenesis and the activity of human osteoclasts. J Bone Miner Res 2008, 23:1097-1105.
33. Hackett J.A., Allard-Chamard H., Sarrazin P., de Fatima Lucena M., Gallant M.A., Fortier I., et al. Prostaglandin production by human osteoclasts in culture. J Rheumatol 2006, 33:1320-1328.
34. Durand M., Boire G., Komarova S.V., Dixon S.J., Sims S.M., Harrison R.E., et al. The increased in vitro osteoclastogenesis in patients with rheumatoid arthritis is due to increased percentage of precursors and decreased apoptosis-the In Vitro Osteoclast Differentiation in Arthritis (IODA) study. Bone 2011, 48:588-596.
35. Seong G.J., Park C., Kim C.Y., Hong Y.J., So H.S., Kim S.D., et al. Mitomycin-C induces the apoptosis of human Tenon's capsule fibroblast by activation of c-Jun N-terminal kinase 1 and caspase-3 protease. Invest Ophthalmol Vis Sci 2005, 46:3545-3552.
36. Fong D., Bisson M., Laberge G., McManus S., Grenier G., Faucheux N., et al. Bone morphogenetic protein-9 activates Smad and ERK pathways and supports human osteoclast function and survival in vitro. Cell Signal 2013, 25:717-728.
37. Hupfeld C.J., Resnik J.L., Ugi S., Olefsky J.M. Insulin-induced beta-arrestin1 Ser-412 phosphorylation is a mechanism for desensitization of ERK activation by Galphai-coupled receptors. J Biol Chem 2005, 280:1016-1023.
38. Kwak H.B., Lee M.S., Kim H.S., Cho H.J., Kim J.W., Lee Z.H., et al. Proteasome inhibitors induce osteoclast survival by activating the Akt pathway. Biochem Biophys Res Commun 2008, 377:1-6.
39. Piva R., Penolazzi L., Borgatti M., Lampronti I., Lambertini E., Torreggiani E., et al. Apoptosis of human primary osteoclasts treated with molecules targeting nuclear factor-kappaB. Ann N Y Acad Sci 2009, 1171:448-456.
40. Weinstein R.S., Manolagas S.C. Apoptosis and osteoporosis. Am J Med 2000, 108:153-164.
41. Benford H.L., McGowan N.W., Helfrich M.H., Nuttall M.E., Rogers M.J. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001, 28:465-473.
42. Wu X., Ahn E.Y., McKenna M.A., Yeo H., McDonald J.M. Fas binding to calmodulin regulates apoptosis in osteoclasts. J Biol Chem 2005, 280:29964-29970.
43. 2 during post-fracture bone remodeling. J Rheumatol 2010, 37:644-649.
44. 2 production. J Biol Chem 2011, 286:2696-2706.
45. Gallant M.A., Samadfam R., Hackett J.A., Antoniou J., Parent J.L., de Brum-Fernandes A.J. Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors. J Bone Miner Res 2005, 20:672-681.
46. Lee Z.H., Lee S.E., Kim C.W., Lee S.H., Kim S.W., Kwack K., et al. IL-1alpha stimulation of osteoclast survival through the PI 3-kinase/Akt and ERK pathways. J Biochem 2002, 131:161-166.
47. 2 induces the production of human beta-defensin-3 in human keratinocytes. Biochem Pharmacol 2010, 79:982-989.
48. Xue L., Gyles S.L., Barrow A., Pettipher R. Inhibition of PI3K and calcineurin suppresses chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2)-dependent responses of Th2 lymphocytes to prostaglandin D(2). Biochem Pharmacol 2007, 73:843-853.
49. 2 receptors, prostanoid DP receptor and CRTH2. Eur J Pharmacol 2007, 557:115-123.
50. Defea K. Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. Br J Pharmacol 2008, 153(Suppl. 1):S298-S309.
51. 2 receptor CRTH2. Mol Pharmacol 2005, 68:393-402.
52. Luttrell L.M., Lefkowitz R.J. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002, 115:455-465.
53. Sun Y., Huang J., Xiang Y., Bastepe M., Juppner H., Kobilka B.K., et al. Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J 2007, 26:53-64.
54. Azzi M., Charest P.G., Angers S., Rousseau G., Kohout T., Bouvier M., et al. Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A 2003, 100:11406-11411.
55. Yee D.K., Suzuki A., Luo L., Fluharty S.J. Identification of structural determinants for G protein-independent activation of mitogen-activated protein kinases in the seventh transmembrane domain of the angiotensin II type 1 receptor. Mol Endocrinol 2006, 20:1924-1934.
56. Wang P., DeFea K.A. Protease-activated receptor-2 simultaneously directs beta-arrestin-1-dependent inhibition and Galphaq-dependent activation of phosphatidylinositol 3-kinase. Biochemistry 2006, 45:9374-9385.
57. Barthet G., Carrat G., Cassier E., Barker B., Gaven F., Pillot M., et al. Beta-arrestin1 phosphorylation by GRK5 regulates G protein-independent 5-HT4 receptor signalling. EMBO J 2009, 28:2706-2718.
58. Schroder R., Merten N., Mathiesen J.M., Martini L., Kruljac-Letunic A., Krop F., et al. The C-terminal tail of CRTH2 is a key molecular determinant that constrains Galphai and downstream signaling cascade activation. J Biol Chem 2009, 284:1324-1336.
59. Kawamura N., Kugimiya F., Oshima Y., Ohba S., Ikeda T., Saito T., et al. Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS One 2007, 2:e1058.
60. Peng X.D., Xu P.Z., Chen M.L., Hahn-Windgassen A., Skeen J., Jacobs J., et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003, 17:1352-1365.
61. Agazie Y., Ischenko I., Hayman M. Concomitant activation of the PI3K-Akt and the Ras-ERK signaling pathways is essential for transformation by the V-SEA tyrosine kinase oncogene. Oncogene 2002, 21:697-707.
62. Burow M.E., Weldon C.B., Melnik L.I., Duong B.N., Collins-Burow B.M., Beckman B.S., et al. PI3-K/AKT regulation of NF-kappaB signaling events in suppression of TNF-induced apoptosis. Biochem Biophys Res Commun 2000, 271:342-345.
63. Reusch H.P., Zimmermann S., Schaefer M., Paul M., Moelling K. Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 2001, 276:33630-33637.
64. Soysa N.S., Alles N., Shimokawa H., Jimi E., Aoki K., Ohya K. Inhibition of the classical NF-kappaB pathway prevents osteoclast bone-resorbing activity. J Bone Miner Metab 2009, 27:131-139.
65. Ozaki K., Takeda H., Iwahashi H., Kitano S., Hanazawa S. NF-kappaB inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells. FEBS Lett 1997, 410:297-300.
66. Wu M., Wang Y., Deng L., Chen W., Li Y.P. TRAF family member-associated NF-kappaB activator (TANK) induced by RANKL negatively regulates osteoclasts survival and function. Int J Biol Sci 2012, 8:1398-1407.